• زمان : ۱۳۹۷/۱/۱۱،‏ ۱۱:۴۸
  • موضوع : تحقیقات

 

 

جایگاه پژوهشکده بیماری های گوارش و کبد دانشگاه علوم پزشکی تهران  در شاخص های تولید علم جهانی

 

بررسی جایگاه «پژوهشکده بیماری های گوارش و کبد» دانشگاه علوم پزشکی تهران در تولید و انتشار علم ایران و سهم آن در تولید علم جهان بر اساس آخرین مستندات گروه علم سنجی وزارت بهداشت، درمان و آموزش پزشکی نشان می دهد این مرکز علمی، با تولید بیش از یکهزار مقاله تا کنون، از رتبه نخست در  میزان استناد به مقالات، اچ ایندکس و همکاری های علمی بین المللی در بین تمام مراکز تحقیقاتی علوم پزشکی کشور ( مرکز تحقیقاتی، پژوهشکده و پژوهشگاه) و از کمترین میزان «خوداستنادی  به مقالات» برخوردار است.

 

این مستندات در گروه علم سنجی وزارت بهداشت، درمان و آموزش پزشکی، با استفاده از نرم افزار و سامانه Scival تهیه شده است. این نرم افزار و سامانه، ابزار علم سنجی و ارزیابی کمی و کیفی عملکرد پژوهشی است که توسط شرکت معتبر بین المللی الزویر طراحی شده و بر پایه شاخص های نوین علم سنجی کار می کند. سامانه Scival اطلاعات پژوهشی بیش از 5 هزار و 500 دانشگاه و موسسه پژوهشی را از بین  220 کشور دنیا ارزیابی و رتبه بندی کرده است. اطلاعات این سامانه بر اساس بانک اطلاعاتی Scopus گردآوری و تجزیه و تحلیل شده است.

برای بازیابی مقالات پژوهشکده بیماری های گوارش و کبد در Scopus نام لاتین خود پژوهشکده همراه با هر مراکز تحقیقاتی پژوهشکده (به استثنای مرکز تحقیقات تازه تاسیس درمانهای سلولی در بیماری های گوارش) به تفکیک در فیلد Affillation جست و جوی Scopus با عملگر  OR، جست و جو و ترکیب شده است که با تلفیق نام دانشگاه و نیز بدون آن ، 735 مقاله به دست آمد. این مقالات به صورت فایل اکسل خروجی گرفته شده و در نرم افزار Scival  بر اساس کد EID آنها ورود اطلاعات شده است.

 

نتایج حاصل از بررسی این مستندات نشان می دهد: پژوهشکده بیماری های گوارش و کبد دانشگاه علوم پزشکی تهران ، صدرنشین کل مراکز تحقیقاتی کشور (پژوهشگاه، پژوهشکده ، مرکز تحقیقاتی ) علوم پزشکی کشور، با زمینه فعالیت علوم بالینی در تولید و انتشار علم است:

مستندات همچنین حاکیست پژوهشکده بیماری های گوارش و کبد دانشگاه علوم پزشکی تهران  دارای بالاترین امتیاز در ارزشیابی و نمره Z مراکز تحقیقاتی دارای ردیف بودجه مستقل علوم پزشکی کشور است:

 

 

 

نگاهی به روند تولید و انتشار مقالات ، میزان استنادات و سهم  پژوهشکده بیماری های گوارش و کبد در تولید علم برتر

 

 

 

 

 به جز  تصویر  بالا ( DDRI the most cited center in TUMS ) که تمامی  735 مقاله را در بر می گیرد، در سایر آنالیزهای این مجموعه به دلیل محدودیت Scival فقط مقالات 2012 تا 2017 میلادی که شامل 420 مقاله پژوهشکده بیماری های گوارش و کبد است، مورد تحلیل قرار گرفته اند. مبنای تمام این تحلیل ها بانک اطلاعاتی Scopus  در مورخ سوم ماه مارچ 2018 میلادی است :

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

نقش مهم ایجاد زیرساختهای پژوهشی در موفقیت های تحقیقاتی پژوهشکده بیماری های گوارش و کبد

 

یکی از مهمترین دلایل موفقیت پژوهشکده گوارش و کبد دانشگاه علوم پزشکی تهران ایجاد زیر ساخت های مهم پژوهشی همچون : تاسیس پایگاه های تحقیقاتی مجهز در مناطقی با شیوع بالای سرطانهای مری (گنبد کاووس) معده (اردبیل) کبد چرب ( فارس)همراه با تاسیس و راه اندازی مطالعات موردی شاهدی و آینده نگر کوهورت با طراحی بسیار دقیق همراه با تاسیس بیوبانک های بزرگ و بسیار مجهز . بوده است. این امکانات موجب شد تا تیمهای پژوهشی  بتوانند با کوشش فراوان در برقراری ارتباط با مهمترین و بزرگترین مطالعات به عضویت این گروهها پذیرفته شوند.

 

List of major DDRI Collaborations network across the World

 

 

1.WHO collaborating center for Study of Cancer and Noncommunicable Disease

DDRI was recognized as a WHO collaborating center for Study of gastrointestinal cancer and noncommunicable disease (NCD) based on vast experience in gastro-intestinal (GI) cancer and NCD research. It was able to make data and scientific evidence more accessible to national and regional researchers and policy makers. The main focus is to reduce the burden of GI cancers in Iran and the region

 

2.Gastric and Esophageal cancer study in Northern Iran (GEMINI)

The Gastro-Esophageal Malignancies in Northern Iran (GEMINI) research project with the original aim of to identify etiologic factors and prevention measures for upper gastrointestinal cancers in Northern provinces of Iran, but its achievements have gone much beyond this initial goal. GEMINI consists of several projects including cancer registries, pilot studies, case-control studies, and the Golestan Cohort Study. GEMINI has been conducted through extensive collaborations between the Digestive Disease Research Center of Tehran University of Medical Sciences with other domestic and international health organizations including National Cancer Institute (NCI) from USA, IARC .the University of Cambridge Cancer Genetics Group (UK), the Karolinska Institute (Sweden), the University of Glasgow (UK), the University of Leeds (UK), the Johns Hopkins University (US), Mount Sinai School of Medicine (US), and the University of Toronto (Canada) were involved in various aspects of the GEMINI project. This network prepared the ground to obtain internal and external funds for the preliminary phase of the project the achievements of GEMINI include producing new knowledge, introducing new research methods, developing and expanding health research and health care infrastructures, investing in human resources, and increasing the awareness and knowledge of policy makers at all levels about the importance of chronic diseases in Iran’s health priorities. The success of GEMINI reveals the feasibility of large-scale health research studies in developing countries and serves as
a successful model not only for health research in Iran, but also for similar research studies in other developing nations
Recently we have launching the GEM Share (GEMINI Shared Repository), available from :https://dceg2.cancer.gov/gemshare


This website will include a list of all GEMINI projects and papers, and serve as the new proposal submission portal, to facilitate the proposal review process, and also prevent the submission of overlapping studies. A list of previously approved project, or a submitted/published paper, available in the system

 

3.Global Burden of Diseases (world’s largest publishing collaboration in science)

The Institute for Health Metrics and Evaluation (IHME) at the University of Washington engages a large network of individual collaborators with specialties in various topic areas to conduct the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and its affiliated projects. GBD is a systematic, scientific effort to quantify the comparative magnitude of health loss due to diseases, injuries, and risk factors by age, sex, and geographies for specific points in time and is the largest and most comprehensive effort to date to measure epidemiological levels and trends worldwide. Collaborators are critical in both the data analysis as well as the policy uptake and proliferation of GBD and affiliated projects. Funded by the Bill & Melinda Gates Foundation, GBD 2010 significantly broadened the scope of previous versions of GBD. Using improved methods for estimating disability weights, GBD 2010 produced estimates for 291 diseases and injuries, 67 risk factors, 1,160 sequelae, 21 regions, 20 age groups, and 187 countries.
Christopher Murray and Alan Lopez began their collaboration on GBD in the early 1990s with a study calculating estimates for eight regions, 107 diseases, and 10 risk factors. Under their leadership, the GBD enterprise currently includes a network of 3,191 collaborators in 140 countries and three territories contributing to what has been recognized as the world’s largest publishing collaboration in science

 


DDRI became a collaborator in 1999 and authored ?? papers till 2017

 

 
DDRI has been an active member of following research group within the GBD

Global Burden of Disease Cancer Collaboration
GBD 2015 Neurological Disorders Collaborator Group
GBD 2016 Risk Factors Collaborators
GBD 2015 Obesity Collaborators
GBD 2016 Causes of Death Collaborators
GBD 2016 Mortality Collaborators
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
GBD 2016 DALYs and HALE Collaborators
GBD 2016 SDG Collaborators
GBD 2015 Eastern Mediterranean Region Collaborators
GBD Iran and its Neighboring Countries, Collaborators
GBD 2015 Tobacco Collaborators.GBD 2015 Healthcare Access and Quality Collaborators
GBD Health Financing Collaborator Network
GBD Child and Adolescent Health Collaboration
GBD 2015 Maternal Mortality Collaborators


4.NCD Risk Factor Collaboration (NCD-RisC)

     NCD Risk Factor Collaboration (NCD-RisC) is a network of health scientists around the world that provides rigorous and timely data on risk factors for non-communicable diseases (NCDs) for 200 countries and territories. The group works closely with the World Health Organization (WHO), through the WHO Collaborating Centre on NCD Surveillance and Epidemiology at Imperial College London. NCD-RisC pools high-quality population-based data using advanced statistical methods, designed specifically for analyzing NCD risk factors. The Collaboration currently has data from over 2,545 population-based surveys from 193 countries since 1957, with nearly 129 million participants whose risk factor levels have been measured. DDRI is an active member of this collaboration since 2016 and is a co-author in publications. NCD-RisC is coordinated by the WHO Collaborating Centre on NCD Surveillance and Epidemiology at Imperial College London, and by its Director, Professor Majid Ezzati. Core funding for the NCD-RisC database is provided by the Wellcome Trust. Work on children and adolescents is funded by a charitable grant from the AstraZeneca Young Health Programme

 

 5.Global surveillance of trends in cancer survival (CONCORD)

CONCORD is the global programme for world-wide surveillance of cancer survival, led by the London School of Hygiene & Tropical Medicine. The CONCORD programme is endorsed by 40 national and international agencies, including WHO EURO, the Organization for Economic Co-operation & Development (OECD) and the World Bank.
CONCORD-3 updates the world-wide surveillance of cancer survival to 2014. It includes 18 cancers and groups of cancer that collectively represent 75% of the global cancer burden.
DDRI joined the CONCORD-3 and co-authored the paper which was published by The Lancet on Tuesday 30 January 2018

 

 

6.International network for study of esophageal squamous cell carcinoma: InterSCOPE Collaboration

Infection with oncogenic human papillomavirus (HPV) types has been linked to various cancers, including cancers of the head and neck. However, the role of HPV in the causation of esophageal squamous cell carcinoma is unclear. InterSCOPE collaboration was established by German cancer research center to study the of HP in ESCC etiology. Six study groups, from South Africa, Australia (, Central and Eastern Europe, Brazil, Iran, and China, agreed to participate and forward their serum samples from histopathologically confirmed esophageal squamous cell carcinoma case subjects as well as serum samples from one or two age- and sex-matched control subjects to the German Cancer Research Center within a prespecified time frame for serological analysis. A total of 1561 case subjects and 2502 control subjects had complete information on all predetermined study-specific confounders.
 There was no serological evidence of an association between esophageal squamous cell carcinoma and HPV in the populations studied. HPV does not appear to be an important risk factor for esophageal squamous cell carcinoma.

 

7.The Epidemiology and Genomics Research Program (EGRP) of the National Cancer Institute (NCI)

is a new resource for Cancer Epidemiology Cohorts: (CEDCD) http://CEDCD.nci.nih.gov
This is  a public, descriptive database of cancer epidemiology cohorts with the goal to facilitate collaborative research efforts among cancer epidemiology cohorts and highlight contributions to cancer research and public health. In this database that is publicly available and searchable. The CEDCD will contain only descriptive information; it will not contain any participant-level data, this database will be updated annually

8.The Stomach Cancer Pooling (StoP) Project

is a consortium of epidemiological studies of gastric cancer. The project started in July 2012, based on a core group of 10 studies. Several investigators joined the project during the last 5 years, and the consortium now counts over 30 studies from different world areas. The main aim of the StoP Project is to examine the role of several lifestyle and genetic determinants in the etiology of gastric cancer, through pooled analyses of individual-level data, after central collection and validation of the original datasets. DDRI is active member from beginning and have co-authored all publications

 

9.The Polaris Observatory Collaborators

Is developed and managed by the CDA Foundation, a non-profit dedicated to the support of studies and projects that increase the knowledge of human diseases, forecast future trends, promote disease prevention, enhance access to treatment and vaccines, and provide healthcare education around the world. The goal of the Polaris Observatory is to provide data, tools, training and decision analytics to support elimination of hepatitis B and C globally by 2030. The activities of the observatory are overseen by an independent advisory board with representatives from global health organizations, academia, liver societies, civil societies and donors.
Polaris observatory provides the most up to date estimates for HCV, HBV and HDV disease burden and strategies that can achieve defined targets.
DDRI has been a collaborator from 2015 and co-author the most important published paper.
Dr .Homie Razavi, (Center for Disease Analysis Foundation) Lafayette, CO 80026, USA is one of the PI.

 

 

 

 

 

 

10.International IBD Genetics Consortium (IIBDGC)

In recent years the IIBDGC has focused on collecting very large datasets from a diverse set of countries via world-wide collaboration. In addition to enabling the discovery of all these genes, we also try to dig a little deeper into what these associations actually mean. Our latest paper takes this further than we ever have before, involving analysts from a dozen research groups and using the latest statistical techniques to look for patterns across the 163 regions.
The combination of all this information allowed us make new statements about IBD risk that no single locus can tell us: IBD is not just genetically similar to other diseases of immunity, but is particularly closely related to certain inflammatory disease such as psoriasis. IBD risk is not only related to changes in the immune system, it is related to a particular subset of immune cells and signals. Not only is IBD risk related to susceptibility to bacterial infection, it is remarkably strongly connected with susceptibility to the family of bacteria that includes leprosy and TB.
DDRI is the only country in Middle east and North Africa as an active member IIBDGC

 


11.CRUK Grand Challenge - Mutation signatures for 5 cancers across 5 continents

Mutograph collaborative study: Somatic mutations and mutational signatures in cancer
  This study which was funded by cancer research UK with the aim of this collaboration is to advance understanding of the causes of cancer through studies of mutational signatures. This will be done by exploring whether different mutational signatures in the DNA of cancers explain geographic differences in cancer incidence, by identifying the specific causes of mutational signatures, and by investigating whether mutational signatures in the DNA of normal cells can be used to monitor cancer-causing exposures in healthy people. Through understanding the causes of cancer, our work may lead to new approaches to prevent it and provide opportunities for more effective application of therapies.
We will focus on 5 cancers that have a clear or suspected link to common lifestyle risk factors for cancer including obesity, hypertension, diabetic history, alcohol consumption and meat consumption.  These include colorectal cancer, renal cancer, pancreatic cancer, and both adenocarcinoma and squamous cell esophageal cancer.  For each of these cancers we will identify and recruit at least 1000 cases from multiple regions across the world that comprise areas of very high risk and low risk.  All cases will be recruited using an extended ICGC protocol that includes extensive background lifestyle information as well as clinical outcome.  Whole genome sequencing of both tumor and germline DNA will be undertaken on all cases, prior to extensive identification of underlying mutation signatures.   This will be supplemented by a focused epigenetic epidemiology study to assess the potential value of methylation patterns to inform cancer etiology.   Mutation signatures and methylation data will subsequently be used to link with suspected risk factor information across high and low risk regions, allowing for identification of the causes of these large international differences, as well as identifying causes at the individual level.   We will also benefit from extensive input on mutation signature profiles from project

 

12.Cambridge Interconnect collaborative nutritional Study of Diabetes mellitus

A systematic cross-validation of previously described exploratory patterns across different populations
Population: Include general population; no limits on age; exclude prevalent cases of type 2 diabetes
• Exposure: any dietary intake (amount/period and/or frequency of intake)
 Outcome: incidence of T2D: self-reported or objectively measured (information on diagnosis date would be ideal)

 

13.The Global Genomic Medicine Collaborative (G2MC, g2mc.org)

To organize a first forum with the goal of enabling leaders of large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and the potential for a larger collaborative sequencing strategy. The NIH, UK Medical Research Council (MRC), and Wellcome Trust have agreed to serve as sponsors, and we expect there may be sponsorship commitments from other HIROs leaders shortly. In contrast to just five years ago, discovering genes for disease is no longer the hard part. Future studies, including those of the IIBDGC, will have to focus not just on discovering new associations, but also on turning those associations into new biological understanding

 

National Scientific Collaborative Networks

1.Surveillance of Risk Factors of Non-Communicable Diseases in Iran (Steps 2016)

2.H. Pylori Eradication clinical trial in Iran collaborators

3.HCV elimination network

4.HBV study networks

5.National Iran Cohort Consortium

6.National Iran Population Based Cancer Registry

 

 

دستاوردهای عملی تولیدات علمی پژوهشکده بیماری های گوارش و کبد

 

 

تحقیقات و مدارک علمی تولید شده در پژوهشکده بیماری های گوارش و کبد دانشگاه علوم پزشکی تهران، علاوه بر تاثیرات مهم در افزایش کمی و ارتقای کیفی تولید علم ایران و افزایش سهم کشور در تولید علم جهان، کمک چشمگیر به پیشرفت دانش بیماری های گوارش و کبد در سطح ملی و بین المللی، به دستاوردهای بسیار مهمی در زمینه ترجمه دانش به راهبردهای عملی تاثیرگذار در ارتقای سطح سلامت رسیده است که فهرست ذیل تنها برخی از مهمترین این دستاوردهاست:

 

1. شناسایی علل بروز و شیوع سرطان ها بویژه سرطان های دستگاه گوارش فوقانی در شمال شرق ایران با اجرای بزرگترین مطالعه کوهورت خاورمیانه  و شمال آفریقا در شمال شرق ایران (گلستان به عنوان داغترین نقطه سرطان مری در جهان)

2. «اثبات قطعیت سرطانزایی تریاک برای نخستین بار در جهان» ، قرارگیری این دستاورد در اولویت فهرست ثبت جهانی و کسب مدال آژانس بین المللی تحقیقات سرطان توسط ایران

3. اثبات تأثیر  نوشیدنی های داغ بر ایجاد سرطان مری برای نخستین بار و ثبت جهانی آن

4.تهیه گزارش ثبت سرطان جمعیتی استان گلستان

5.اجرای برنامه جامع «ارتقای ثبت سرطان در ایران» و تهیه بانک اطلاعاتی جغرافیایی (GIC) برای نطام ثبت سرطان در ایران

6.. ورود «گزارش ثبت سرطان ایران» به مرجع جهانی «سرطان در 5 قاره جهان» برای نخستین بار

7. تشکیل بیوبانک مدرن برای تشخیص زودهنگام بیماری ها و شناسایی عوامل خطر

8. راه‌اندازي سيستم مولكولي تعيين بار ويروس هپاتيت C با استفاده از تكنيك Real Time RT-PCR

9. تولید داروی ترکیبی ارزان ، در دسترس و  بسيار موثر عليه هپاتيت C با نام سووداک پس از چند سال تحقیق و عرضه آن به بازار دارويي کشور

10.تولید داروی مهم  «پلی پیل» با ترکیب مجموع داروهاي آسپيرين، داروهاي ضد فشارخون و  کاهنده چربي خون برای پیشگیری از بیماری های مزمن غیرواگیر، بویژه سکته های قلبی و مغزی و  رسیدن به هدف بسیار مهم «کاهش مرگهای زودرس» در نظام سلامت ایران

11.پایه گذاری مطالعات کوهورت در 21 استان ایران تا کنون، با استفاده از تجربیات مطالعه کوهورت گلستان ، برای پیشگیری از بیماری های مزمن و کمک به کاهش بار سنگین بیماری های مزمن غیرواگیر در ایران

12. درمان بيماري کبد چرب غيرالکلي با داروي پروبوکل براي اولين بار در جهان و ايران سال

13. درمان هپاتيت اتوايميون با سيکلوسپرين خوراکي در بالغين براي نخستین بار در جهان و ايران

15. ارائه روش درمانی ساده و موثر غير جراحي براي بيماري آشالازي که تاکنون برای صدها بيمار در ايران با موفقيت انجام شده است

15. طراحي و ارائه کيت هاي تشخيصي براي تست تنفسي (UBT) براي اولين بار در کشور

16. طراحي و ارائه کيت هاي تشخيصي براي آزمايش هپاتيت B ، C و شمارش ويروس براي اولين بار در کشور

17. شناسایی بیماران مبتلا به سلیاک در سطح گسترده در کشور و ایجاد «نظام ثبت بیماری سلیاک در ایران»

18. کمک به طراحي و توليد نخستین کيت هاي تشخيصي بيماري سلياک در ايران

19. کمک به ریشه کنی هلیکوباکتر پیلوری برای کاهش خطر سرطان معده در ایران و جهان با معرفی موثرترین درمان استاندارد و انجام بيش از 15 پژوهش باليني RCT

20.استفاده از سلولهاي بنيادي در درمان سيروز کبدي براي نخستین بار در جهان با همکاري مرکز تحقيقات خون و انکولوژي دانشگاه علوم پزشکي تهران و مؤسسه رويان جهاد دانشگاهي

21. ایجاد نظام ثبت بیماری IBD (برای بیماران مبتلا به بیماری های مزمن التهابی روده) با اجرای مطالعات همگروهی و ژنتیک در سطح ایران

 22 .حمایت از صنعت دارویی ایران از طریق اجرای مطالعات RCT برای بررسی کیفیت داروهای ایرانی ، مقایسه با نمونه های مشابه خارجی و اثبات کیفیت مناسب داروهای تولید داخل از طریق این مطالعات و کمک به افزایش اعتماد پزشکان در تجویز داروهای ایرانی